Kristen Kluska

Cantor Fitzgerald | Healthcare

Kristen Kluska is an analyst from Cantor Fitzgerald specializing in the Healthcare sector. Ranked #2396 out of 4774 analysts, they have issued 23 stock ratings with a success rate of 67.30% and an average return of 17.13%.

Kristen Kluska has a well-established track record, with 23 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 67.30% and an average return of 17.13%, underscoring their expertise and ability to identify winning opportunities for investors.

#2396

Out of 4774

23

Total Ratings

+67.30%

Success Rate

+17.13%

Average Return

Recent Ratings Analysis

CAPR

Jul 30, 2026

Target

$3.50

Current

$8.81

Performance

110.26%

Kristen Kluska rated CAPR as Neutral on Jul 30, 2026, setting a price target of 3.5. Despite the Hold call, shares climbed 110.26% to 8.81, revealing unexpected momentum.

CLDX

Jul 22, 2026

Target

$61.00

Current

$39.18

Performance

12.68%

On Jul 22, 2026, CLDX was given a Overweight rating by Kristen Kluska, with a target price of 61. The stock rallied 12.68% after the rating, narrowing the gap to the target of 61 and validating the bullish stance.

PTCT

Jul 16, 2026

Target

$130.00

Current

$66.48

Performance

-15.33%

PTCT received a Overweight rating from Kristen Kluska on Jul 16, 2026, aiming for 130. The rating hasn’t played out as hoped, with the stock trading 15.33% below expectations.

SUPN

Jul 09, 2026

Target

$67.00

Current

$41.49

Performance

-14.89%

On Jul 09, 2026, Kristen Kluska published a Overweight outlook on SUPN, with a target of 67. Market action contradicted the Buy thesis, as shares slipped to 41.49.

RNA

Jun 18, 2026

Target

$25.00

Current

$10.21

Performance

-19.35%

Kristen Kluska on Jun 18, 2026 assigned RNA a Overweight rating, with a price target of 25. The call has struggled to gain traction, with shares losing 19.35%.

ZVRA

Jun 08, 2026

Target

$34.00

Current

$12.05

Performance

-0.33%

On Jun 08, 2026, Kristen Kluska reaffirmed ZVRA with a Overweight rating, targeting 34. Market indecision has kept the 34 target in a holding pattern.

RARE

May 21, 2026

Target

$96.00

Current

$13.61

Performance

-42.60%

RARE was rated Overweight by Kristen Kluska on May 21, 2026, with a price objective of 96. This case shows how bullish projections can fail, with the stock now below 13.61.

SLNO

Apr 06, 2026

Target

$53.00

Current

$53.01

Performance

1.45%

On Apr 06, 2026, Kristen Kluska initiated coverage on SLNO with a Neutral rating and target of 53. The stock’s lack of movement around 53.01 aligned with a cautious approach.

RNAC

Mar 09, 2026

Target

$16.00

Current

$8.04

Performance

-10.86%

Kristen Kluska issued a Overweight recommendation for RNAC on Mar 09, 2026, price target set at 16. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

QURE

Mar 02, 2026

Target

$55.00

Current

$44.93

Performance

327.90%

On Mar 02, 2026, QURE was evaluated by Kristen Kluska, who gave a Neutral rating and target of 55. Investors who stayed in despite the Hold saw upside of 327.90%.

IRON

Feb 17, 2026

Target

$153.00

Current

$68.92

Performance

5.11%

Kristen Kluska rated IRON as Overweight on Feb 17, 2026, setting a price target of 153. The call has proven timely, with shares rising 5.11% toward the price target of 153.

EPRX

Jan 15, 2026

Target

$19.00

Current

$8.07

Performance

-7.98%

On Jan 15, 2026, EPRX was given a Overweight rating by Kristen Kluska, with a target price of 19. Despite the Buy call, shares fell from 8.07 to 8.07, challenging the optimistic stance.

FOLD

Dec 19, 2025

Target

$21.00

Current

$14.49

Performance

2.19%

FOLD received a Neutral rating from Kristen Kluska on Dec 19, 2025, aiming for 21. Shares remained flat at 14.49, aligning with the neutral rating.

DBVT

Dec 17, 2025

Target

$48.00

Current

$12.35

Performance

-45.23%

On Dec 17, 2025, Kristen Kluska published a Overweight outlook on DBVT, with a target of 48. Market action contradicted the Buy thesis, as shares slipped to 12.35.

FULC

Dec 08, 2025

Target

$24.00

Current

$3.79

Performance

-70.82%

Kristen Kluska on Dec 08, 2025 assigned FULC a Overweight rating, with a price target of 24. The call has struggled to gain traction, with shares losing 70.82%.

LXEO

Dec 01, 2025

Target

$19.00

Current

$4.21

Performance

-52.80%

On Dec 01, 2025, Kristen Kluska reaffirmed LXEO with a Overweight rating, targeting 19. Shares slid 52.80% despite the recommendation, highlighting downside risks.

RIGL

Nov 05, 2025

Target

$38.00

Current

$45.35

Performance

19.82%

RIGL was rated Neutral by Kristen Kluska on Nov 05, 2025, with a price objective of 38. Despite caution, upside momentum rewarded risk-takers with gains to 45.35.

MNPR

Aug 27, 2025

Target

$74.00

Current

$108.32

Performance

211.17%

On Aug 27, 2025, Kristen Kluska initiated coverage on MNPR with a Overweight rating and target of 74. The stock’s climb of 211.17% since the call highlights the foresight in the rating.

XFOR

Mar 26, 2025

Target

$3.00

Current

$3.62

Performance

-55.21%

Kristen Kluska issued a Overweight recommendation for XFOR on Mar 26, 2025, price target set at 3. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

SRPT

Mar 19, 2025

Target

$163.00

Current

$20.92

Performance

-73.84%

On Mar 19, 2025, SRPT was evaluated by Kristen Kluska, who gave a Overweight rating and target of 163. Investors saw limited payoff as shares fell short of the 163 target.

MREO

Mar 18, 2025

Target

$7.00

Current

$0.28

Performance

-88.93%

Kristen Kluska rated MREO as Overweight on Mar 18, 2025, setting a price target of 7. The stock has underperformed, dropping 88.93% despite the bullish target of 7.

ADMA

Mar 04, 2025

Target

$25.00

Current

$9.14

Performance

-46.27%

On Mar 04, 2025, ADMA was given a Overweight rating by Kristen Kluska, with a target price of 25. Despite the Buy call, shares fell from 9.14 to 9.14, challenging the optimistic stance.

ETNB

Jan 02, 2025

Target

$29.00

Current

$14.84

Performance

85.96%

ETNB received a Overweight rating from Kristen Kluska on Jan 02, 2025, aiming for 29. Momentum has favored the Buy call, with shares climbing from 14.84 to 14.84, rewarding those who trusted the recommendation.

AQST

Dec 17, 2024

Target

$17.00

Current

$4.88

Performance

26.75%

On Dec 17, 2024, Kristen Kluska published a Overweight outlook on AQST, with a target of 17. Shares gained 26.75%, underscoring the accuracy of the bullish outlook toward 17.

ESPR

Dec 17, 2024

Target

$8.00

Current

$3.18

Performance

29.27%

Kristen Kluska on Dec 17, 2024 assigned ESPR a Overweight rating, with a price target of 8. The Buy call aligned well with market performance, producing a gain of 29.27%.

CDXS

Nov 22, 2024

Target

$11.00

Current

$1.48

Performance

-67.90%

On Nov 22, 2024, Kristen Kluska reaffirmed CDXS with a Overweight rating, targeting 11. Shares slid 67.90% despite the recommendation, highlighting downside risks.

ABEO

Sep 20, 2024

Target

$18.00

Current

$5.43

Performance

-9.80%

ABEO was rated Overweight by Kristen Kluska on Sep 20, 2024, with a price objective of 18. This case shows how bullish projections can fail, with the stock now below 5.43.

HUMA

Sep 20, 2024

Target

$13.00

Current

$0.56

Performance

-89.21%

On Sep 20, 2024, Kristen Kluska initiated coverage on HUMA with a Overweight rating and target of 13. The Buy call has yet to be validated as shares remain 12.44 away from the target.

SKYE

Sep 20, 2024

Target

$14.00

Current

$1.99

Performance

-92.08%

Kristen Kluska issued a Overweight recommendation for SKYE on Sep 20, 2024, price target set at 14. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

TSHA

Jun 20, 2024

Target

$7.00

Current

$5.01

Performance

81.52%

On Jun 20, 2024, TSHA was evaluated by Kristen Kluska, who gave a Overweight rating and target of 7. This case illustrates how a timely bullish rating can translate into tangible gains of 81.52%.

ATNM

Apr 30, 2024

Target

$21.00

Current

$1.28

Performance

-83.38%

Kristen Kluska rated ATNM as Overweight on Apr 30, 2024, setting a price target of 21. The stock has underperformed, dropping 83.38% despite the bullish target of 21.

Frequency Asked Questions

Who is Kristen Kluska?

Kristen Kluska is an analyst from Cantor Fitzgerald specializing in the Healthcare sector.

What is Kristen Kluska's success rate?

Kristen Kluska currently has a success rate of +67.30%.

How many ratings has Kristen Kluska issued?

Kristen Kluska has issued 23 stock ratings so far.

What is the average return of Kristen Kluska's calls?

Their stock ratings have generated an average return of +17.13%.

What is Kristen Kluska's ranking?

Kristen Kluska is ranked #2396 out of 4774 analysts.

What types of ratings does Kristen Kluska give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Kristen Kluska?

You can follow Kristen Kluska by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Kristen Kluska?

Their latest rating was a Hold on CAPR issued on 2026-07-30.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep